Jilin Provincial Medicine Anti-Tumor Engineering Center, the Second Hospital of Jilin University, Changchun 130041, Jilin Province, China.
Department of Gastroenterology, the Second Hospital of Jilin University, Changchun 130041, Jilin Province, China.
World J Gastroenterol. 2020 Feb 14;26(6):670-685. doi: 10.3748/wjg.v26.i6.670.
Esophageal carcinoma is a malignant gastrointestinal tumor with a very poor prognosis. MicroRNA (miR)-1304 is a newly discovered non-coding RNA, which shows differential expression in other cancers, and its clinical value in esophageal carcinoma remains unclear.
To explore the expression of miR-1304 in patients with esophageal carcinoma and its clinical value.
The expression of miR-1304 in patients with esophageal carcinoma was analyzed based on the data on miR in esophageal carcinoma downloaded from The Cancer Genome Atlas database. Quantitative real-time polymerase chain reaction was adopted to determine the expression of miR-1304 in the tissues and serum of patients. The clinical diagnostic value of miR-1304 and independent factors for recurrence and prognosis of esophageal carcinoma were then analyzed. The potential target genes of miR-1304 were predicted, and then analyzed based on gene ontology, Kyoto Encyclopedia of Genes, and Genomes, and protein-protein interaction.
The expression of miR-1304 in the tissues and serum of patients with esophageal carcinoma increased, and was also increased according to the database. Patients with high expression of miR-1304 suffered increased rates of tumor ≥ 3 cm, low differentiation and stage II + III. miR-1304 had a diagnostic value in identifying esophageal carcinoma, tumor size, differentiation and TNM stage. Tumor size, differentiation, TNM stage, and miR-1304 were independent risk factors for recurrence of esophageal carcinoma, and they had certain predictive and diagnostic value for the recurrence of esophageal carcinoma. Seventy-eight patients showed a 3-year survival rate of 38.46%, and patients with high expression of miR-1304 had a relatively lower survival rate. Multivariate analysis revealed that tumor size, differentiation, recurrence and miR-1304 were independent factors for the prognosis of patients. MiRTarBase, miRDB, and Targetscan predicted 20 target genes in total. Gene ontology enrichment analysis found 18 functions with < 0.05, and Kyoto Encyclopedia of Genes, and Genomes analysis found 11 signal pathways with < 0.05. String analysis of protein co-expression found 269 relationship pairs, of which co-expression with epidermal growth factor was the most common.
miR-1304 can be used as a potential indicator for the diagnosis and recurrence of esophageal carcinoma and for survival of patients with this disease.
食管癌是一种恶性胃肠道肿瘤，预后极差。微小 RNA（miR）-1304 是一种新发现的非编码 RNA，在其他癌症中表达差异，但其在食管癌中的临床价值尚不清楚。
探讨 miR-1304 在食管癌患者中的表达及其临床价值。
根据从癌症基因组图谱数据库下载的食管癌 miR 数据，分析食管癌患者 miR-1304 的表达。采用定量实时聚合酶链反应测定患者组织和血清中 miR-1304 的表达。然后分析 miR-1304 对食管癌复发和预后的独立影响因素。预测 miR-1304 的潜在靶基因，然后基于基因本体、京都基因与基因组百科全书和蛋白质-蛋白质相互作用进行分析。
食管癌患者组织和血清中 miR-1304 的表达增加，数据库中亦如此。miR-1304 高表达的患者肿瘤≥3cm、低分化和Ⅱ+Ⅲ期的比例增加。miR-1304 对食管癌、肿瘤大小、分化和 TNM 分期具有诊断价值。肿瘤大小、分化、TNM 分期和 miR-1304 是食管癌复发的独立危险因素，对食管癌复发具有一定的预测和诊断价值。78 例患者 3 年生存率为 38.46%，miR-1304 高表达患者生存率相对较低。多因素分析显示，肿瘤大小、分化、复发和 miR-1304 是患者预后的独立因素。MiRTarBase、miRDB 和 Targetscan 共预测了 20 个靶基因。基因本体富集分析发现 18 个功能具有 <0.05，京都基因与基因组百科全书分析发现 11 个信号通路具有 <0.05。蛋白质共表达的 String 分析发现 269 个关系对，其中与表皮生长因子共表达最常见。
miR-1304 可作为诊断、食管癌复发和患者生存的潜在指标。
